Innophore, a Graz-based bioinformatics company, has partnered with NVIDIA to develop artificial intelligence for the early detection of drug side effects. Together, they created a comprehensive dataset of human protein structures, enabling AI-driven predictions of how therapeutic compounds interact with molecular targets. The approach aims to identify potential adverse reactions much earlier in the drug development pipeline, potentially saving years of costly clinical trials and improving patient safety.

Read the full article at Der Standard